Pheochromocytoma and Paraganglioma (PPGL)

Pheochromocytoma and paraganglioma (PPGLs) are catecholamine-secreting neuroendocrine tumors arising from chromaffin cells of the adrenal medulla and extra-adrenal autonomic ganglia. Though rare — affecting 3–8 people per million per year — PPGLs are clinically significant because they are potentially curable with surgery, yet lethal if missed. The classic triad of episodic palpitations, severe headache, and drenching sweats should trigger immediate biochemical screening. Modern genetic testing has revealed that 35–40% of all PPGLs arise from germline mutations, fundamentally shifting how these tumors are managed and how families are counseled.

Table of Contents

  1. Overview and Definition
  2. Epidemiology
  3. Hereditary PPGL Syndromes
  4. The Rule of 10s (Historical and Modern)
  5. Clinical Presentation
  6. Biochemical Diagnosis
  7. Imaging and Functional Imaging
  8. Treatment: Surgical Preparation
  9. Treatment: Surgery and Advanced Disease
  10. Genetic Screening and Family Cascade Testing
  11. Key Research Papers
  12. Featured Videos
  13. Connections

1. Overview and Definition

PPGLs are catecholamine-secreting neuroendocrine tumors arising from chromaffin cells — specialized cells that stain darkly with chromic acid salts and derive embryologically from the neural crest. Pheochromocytoma refers specifically to tumors arising from the adrenal medulla, accounting for 80–85% of all PPGLs. Paraganglioma refers to tumors arising from extra-adrenal chromaffin tissue distributed along the sympathetic and parasympathetic chains.

The distinction between sympathetic and parasympathetic paragangliomas is clinically critical:

Together, all tumors of this lineage are grouped as PPGLs in modern nomenclature, reflecting shared genetic drivers, management principles, and the importance of germline testing across the full spectrum.

Back to Table of Contents

2. Epidemiology

PPGLs are rare tumors with an estimated incidence of 3–8 cases per million per year in the general population. They are found in approximately 0.1–0.6% of all hypertensive patients, making them an important — if uncommon — secondary cause of hypertension. In autopsy series, the prevalence is higher than expected from clinical diagnoses, suggesting many cases go undetected during life.

Age distribution: PPGLs affect all age groups. In adults, the peak incidence is in the fourth to fifth decades. In children, PPGLs are more likely to be hereditary, extra-adrenal, bilateral, and multifocal — features that should prompt early genetic evaluation. Pediatric presentations are nearly always familial.

Sex distribution: Roughly equal between males and females, though head-neck paragangliomas (particularly jugulotympanic tumors) have a slight female predominance.

The hereditary shift: Perhaps the most important epidemiological development of the past two decades is the recognition that hereditary PPGLs are far more common than the historically taught 10%. Modern germline sequencing studies consistently show that 30–40% of all PPGL patients harbor a germline mutation, even without a family history, even with unilateral sporadic-appearing disease. This has led to the current recommendation that all PPGL patients receive genetic counseling and testing, regardless of clinical presentation.

Back to Table of Contents

3. Hereditary PPGL Syndromes

At least 20 genes have been identified in which germline mutations predispose to PPGL. The major syndromes — each with a distinct phenotypic and biochemical fingerprint — are:

MEN2 (RET mutation)

Multiple endocrine neoplasia type 2A and 2B are caused by activating mutations in the RET proto-oncogene. Pheochromocytoma occurs in 50% of MEN2A patients and roughly 50% of MEN2B patients over a lifetime. MEN2 pheochromocytomas are characteristically bilateral and adrenal, and they hypersecrete epinephrine (not just norepinephrine). The medullary thyroid carcinoma component of MEN2A/B takes priority in management — thyroidectomy first, then pheochromocytoma workup.

Von Hippel-Lindau (VHL mutation)

VHL disease causes bilateral adrenal pheochromocytomas in approximately 10–20% of patients. VHL-associated pheochromocytomas have distinctive clear cell histology, predominantly secrete normetanephrine (norepinephrine pathway), and are rarely malignant. Patients also have renal clear cell carcinomas, hemangioblastomas (cerebellum, spinal cord, retina), and pancreatic cysts/neuroendocrine tumors — a constellation that should prompt VHL testing.

NF1 (Neurofibromatosis Type 1)

Pheochromocytoma occurs in approximately 1–5% of NF1 patients, typically presenting later in life than other hereditary forms. NF1 pheochromocytomas are almost always unilateral and adrenal, and they hypersecrete epinephrine. The diagnosis of NF1 is usually already known from the skin manifestations (cafe-au-lait macules, cutaneous neurofibromas, Lisch nodules), making genetic testing for pheochromocytoma workup straightforward.

SDH Mutations (the "SDH cluster")

Mutations in the succinate dehydrogenase complex subunit genes (SDHA, SDHB, SDHC, SDHD, SDHAF2) represent the largest hereditary PPGL category:

Germline genetic testing is recommended for all PPGL patients. Younger age at presentation, bilateral or multifocal tumors, extra-adrenal location, malignant behavior, or head-neck location increases the prior probability of finding a germline mutation — but none of these features is required for testing to be warranted.

Back to Table of Contents

4. The Rule of 10s (Historical and Modern)

Medical students and residents have long learned pheochromocytoma through the "Rule of 10s" — a memorable but now outdated teaching heuristic. The original rule stated:

Modern data, driven by large multicenter registries and routine germline sequencing, has revised every one of these estimates upward:

Feature Historical "Rule of 10s" Modern Estimate
Bilateral 10% 10–20% (higher in MEN2/VHL)
Extra-adrenal 10% 15–25%
Malignant (adrenal) 10% 10–17%
Malignant (extra-adrenal) 10% 15–35%
Malignant (SDHB mutation) 10% 25–40%
Hereditary 10% 35–40% with modern germline testing
In children 10% 10–20% (usually familial)

The Rule of 10s persists in medical education as a useful memory aid, but clinicians should not apply it to actual risk stratification or management decisions. In particular, the 10% hereditary figure is dangerously low — using it could lead to undertesting and missed familial syndromes with severe consequences for patients and their relatives.

Back to Table of Contents

5. Clinical Presentation

The clinical hallmark of functioning PPGL is the catecholamine excess syndrome. The classic triad — episodic palpitations, severe headache, and diaphoresis — occurs in 50–70% of patients with secreting tumors. However, presentation is highly variable, and a significant minority present with sustained rather than paroxysmal hypertension, or with an incidental adrenal mass without overt symptoms.

Paroxysmal Hypertensive Crises ("Spells")

Characteristic spells involve sudden, severe blood pressure elevation (systolic often exceeding 250 mmHg) accompanied by intense headache, profuse sweating, palpitations, and pallor — not flushing. The pallor is key: catecholamines cause intense peripheral vasoconstriction (unlike carcinoid syndrome, which causes cutaneous vasodilation and flushing). Spells typically resolve within minutes but can recur multiple times per day or be separated by weeks. Between spells, blood pressure may be normal.

Triggers include:

Sustained Hypertension

Approximately 50% of PPGL patients have persistent rather than episodic hypertension. These patients may be misdiagnosed as essential hypertension for years. PPGL should be considered in any young patient with refractory or difficult-to-control hypertension, especially with associated weight loss, hyperglycemia, or a family history of relevant syndromes.

Catecholamine-Induced Cardiomyopathy

Prolonged or intense catecholamine excess causes a reversible Takotsubo-like cardiomyopathy with left ventricular dysfunction, sometimes presenting as acute heart failure or cardiogenic shock. This is an underappreciated presentation of PPGL; echocardiography showing apical ballooning or diffuse hypokinesis in the context of new-onset heart failure should prompt PPGL screening, particularly if no obstructive coronary artery disease is identified. The cardiomyopathy typically reverses after tumor removal.

Metabolic Manifestations

Catecholamines inhibit insulin secretion and stimulate glycogenolysis and gluconeogenesis, producing hyperglycemia and sometimes frank diabetes mellitus. Patients may also present with unexplained weight loss, hypermetabolism (elevated basal metabolic rate), and heat intolerance — a picture that can mimic hyperthyroidism.

Non-Secreting Head-Neck Paragangliomas

These tumors produce no catecholamines and present purely through mass effect:

Back to Table of Contents

6. Biochemical Diagnosis

Biochemical confirmation of catecholamine excess is the essential first step before any imaging. Imaging a clinically unsuspected adrenal incidentaloma without first establishing biochemical secretion risks both false-positive and false-negative conclusions.

Plasma Free Metanephrines — First-Line Test

Plasma free metanephrines (metanephrine + normetanephrine) are the single most sensitive test for PPGL, with sensitivity of 96–99% for adrenal pheochromocytoma. Metanephrines are the O-methylated metabolites of catecholamines, produced continuously within the tumor (not episodically), making them far more reliable than measuring catecholamines themselves during an interspell period.

Interpretation:

False positives arise from: tricyclic antidepressants, levodopa, acetaminophen (interferes with some assays), physiological stress, renal failure, and obstructive sleep apnea. A normal plasma metanephrine result has a high negative predictive value and essentially rules out functioning PPGL.

24-Hour Urine Metanephrines and Catecholamines

Urine fractionated metanephrines and catecholamines (epinephrine, norepinephrine, dopamine) collected over 24 hours provide a second-line or confirmatory test. They are less sensitive than plasma metanephrines but more specific in populations with a low pre-test probability (avoiding false positives). Urine dopamine elevation disproportionate to other catecholamines suggests SDH-mutated PPGL.

Chromogranin A

Chromogranin A is a neuroendocrine secretory protein elevated in most PPGLs. It is not specific enough for diagnosis but serves as a useful tumor marker for monitoring response to treatment and detecting recurrence in patients with known PPGL, particularly metastatic disease.

Biochemical Phenotyping Guides Genetics

The catecholamine secretory pattern provides a clue to the underlying mutation:

Back to Table of Contents

7. Imaging and Functional Imaging

Imaging is initiated only after biochemical confirmation of catecholamine excess. The goal is tumor localization, not diagnosis — the diagnosis is biochemical. In patients with head-neck paragangliomas (non-secreting), imaging is the primary modality since biochemistry may be normal.

CT Abdomen and Pelvis

First-line structural imaging for suspected adrenal pheochromocytoma. Features on non-enhanced CT:

Caution: contrast-enhanced CT can theoretically trigger a hypertensive crisis, though modern low-osmolarity agents carry very low risk. Ensure adequate alpha-blockade before proceeding with contrast if PPGL is strongly suspected.

MRI

MRI is preferred over CT in several settings: extra-adrenal tumor localization (no radiation, excellent soft-tissue contrast), pediatric patients, pregnancy, and iodinated contrast allergy. The classic MRI finding is T2 hyperintensity ("light-bulb" sign) — pheochromocytomas appear extremely bright on T2-weighted sequences, reflecting their high water content and vascularity. This finding is highly suggestive but not pathognomonic (other neuroendocrine tumors can be T2-bright).

68Ga-DOTATATE PET (Somatostatin Receptor Imaging)

68Ga-DOTATATE PET/CT has become the functional imaging modality of choice for most PPGLs. PPGLs express somatostatin receptor type 2 (SSTR2), making them avid for DOTATATE. Advantages:

123I-MIBG Scintigraphy

Meta-iodobenzylguanidine (MIBG) is taken up by chromaffin cells via the norepinephrine transporter. 123I-MIBG scintigraphy has been the traditional functional imaging modality for PPGL but has largely been superseded by DOTATATE PET for localization. However, MIBG scanning retains importance for treatment planning: only MIBG-avid tumors are eligible for therapeutic 131I-MIBG (Azedra). All patients being considered for Azedra therapy should have a diagnostic MIBG scan first.

Back to Table of Contents

8. Treatment: Surgical Preparation

Pre-operative medical preparation is mandatory before any surgical intervention for functioning PPGL. Unblocked tumor manipulation during surgery causes massive catecholamine release, resulting in a life-threatening hypertensive crisis, cardiac arrhythmias, and potentially death. The goal of pre-operative blockade is to normalize blood pressure, restore plasma volume, and protect the myocardium.

Alpha-Adrenergic Blockade — First Step

Phenoxybenzamine (irreversible, non-selective alpha-blocker) is the traditional first-line agent. Starting dose 10 mg twice daily, titrated over 7–14 days until blood pressure is controlled (<130/80 mmHg seated; orthostatic drop is expected and indicates adequate blockade). Orthostatic hypotension, nasal congestion, and reflex tachycardia are expected side effects. Phenoxybenzamine provides the most reliable intraoperative hemodynamic control and is preferred by most major centers.

Selective alpha-1 blockers (doxazosin, terazosin, prazosin) are an alternative. They cause less reflex tachycardia and are better tolerated in outpatients. Some evidence suggests slightly less hemodynamic stability intraoperatively compared to phenoxybenzamine, but outcomes data are reassuring in experienced centers.

Beta-Blockade — Only After Alpha-Blockade Is Established

Beta-blockers address the reflex tachycardia from alpha-blockade and provide myocardial protection. The critical rule: never initiate a beta-blocker before adequate alpha-blockade. Without alpha-blockade, beta-blockade removes the vasodilatory beta-2 effect, leaving unopposed alpha-1 vasoconstriction — producing paradoxical, severe hypertension. Propranolol or metoprolol is typically started 48–72 hours before surgery after alpha-blockade is established. Target heart rate 60–70 bpm.

Volume Expansion

Chronic catecholamine excess causes contracted plasma volume (the vasculature is chronically vasoconstricted, suppressing renin-angiotensin and volume expansion). After alpha-blockade dilates vessels, patients experience symptomatic orthostatic hypotension unless volume is repleted. High-salt diet (5–10 g/day added salt) and liberal fluid intake are recommended for 7–14 days pre-operatively. This prevents severe intraoperative and immediate post-operative hypotension when the catecholamine source is removed.

Calcium Channel Blockers

Amlodipine or nicardipine may be added as adjuncts in patients with severe or refractory hypertension, or as the primary agent in patients with volume depletion or intolerance to alpha-blockers. Calcium channel blockers are less effective as monotherapy for intraoperative crisis prevention but useful in combination.

Back to Table of Contents

9. Treatment: Surgery and Advanced Disease

Localized Disease — Surgery

Laparoscopic adrenalectomy is the preferred approach for localized adrenal pheochromocytoma ≤6 cm in diameter. It offers equivalent oncologic outcomes with less morbidity and shorter recovery than open surgery. Cortical-sparing adrenalectomy may be considered for bilateral tumors (particularly in MEN2 and VHL patients) to preserve adrenal cortical function, though it carries a higher recurrence risk. Open adrenalectomy is indicated for large tumors (>6 cm), invasive or locally advanced disease, malignant tumors, or extra-adrenal paragangliomas with adjacent organ involvement. Head-neck paragangliomas require otolaryngologic or neurosurgical expertise depending on location.

Intraoperative Management

Invasive arterial monitoring is essential. Anesthesiologists should be experienced with PPGL cases. Hypertensive crises during tumor manipulation are managed with intravenous phentolamine (5 mg bolus) or nitroprusside infusion. Hypotension after tumor removal (from sudden catecholamine withdrawal plus volume contraction) is managed with aggressive fluid resuscitation; vasopressors may be needed temporarily.

Metastatic PPGL — Systemic Therapies

Metastatic PPGL is defined by the presence of PPGL cells at sites where chromaffin tissue does not normally exist (lymph nodes, bone, liver, lung). There is no accepted systemic cure, but several agents provide disease control:

Surveillance After Resection

All patients require lifelong biochemical follow-up regardless of whether the tumor was benign or malignant: annual plasma metanephrines for at least 10 years (or lifelong in hereditary cases). Late recurrences and metachronous metastases are well-documented even for apparently benign primary tumors. Imaging (CT or MRI) is guided by biochemical surveillance results and genetic risk.

Back to Table of Contents

10. Genetic Screening and Family Cascade Testing

The 2014 Endocrine Society Clinical Practice Guideline recommends that all patients with PPGL undergo genetic counseling and germline testing, irrespective of age, tumor location, bilaterality, or family history. This recommendation reflects the 35–40% prevalence of germline mutations — far too high to limit testing to high-risk clinical profiles.

Genetic Testing Approach

Multi-gene panel testing covering all major PPGL susceptibility genes (RET, VHL, NF1, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, MAX, and others) is now the standard of care. The panel is ordered by a genetic counselor or endocrinologist experienced with hereditary tumor syndromes. The biochemical phenotype (which catecholamine is elevated) and tumor characteristics (location, bilaterality, age of onset) can guide interpretation of variants of uncertain significance.

When a Germline Mutation Is Found

First-degree relatives (parents, siblings, children) are offered cascade genetic testing — targeted testing for the specific family mutation. This allows identification of mutation carriers who have not yet developed tumors and can enter surveillance programs before disease develops.

SDHD Imprinting — A Special Case

SDHD mutations exhibit maternal imprinting: the maternally inherited copy of SDHD is epigenetically silenced. This means that a mutation inherited from the father causes disease, while the same mutation inherited from the mother does not (the silenced maternal copy is functionally absent, but the paternally-derived copy is also now mutated — leaving no functional SDHD). Clinicians must document which parent transmitted the mutation; paternal inheritance warrants full surveillance, maternal inheritance generally does not. SDHAF2 follows the same imprinting pattern.

Back to Table of Contents

11. Key Research Papers

  1. Eisenhofer G et al. "Biochemical Diagnosis of Pheochromocytoma and Paraganglioma." N Engl J Med. 2004. PMID 14973213
  2. Lenders JW et al. "Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline." J Clin Endocrinol Metab. 2014;99:1915–42. PMID 24893135
  3. Timmers HJ et al. "Mutations in succinate dehydrogenase B (SDHB) and SDHD genes in PPGL." J Med Genet. 2007;44:e115. PMID 17873122
  4. Pacak K et al. "Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma." Ann Intern Med. 2001;134:315–29. PMID 11182843
  5. Jimenez C et al. "Management of pheochromocytoma and paraganglioma: summary of the Endocrine Society Clinical Practice Guideline." Ann Intern Med. 2015. PMID 26305719
  6. Darr R et al. "Pheochromocytoma — state of the art and future aspects of drug development." Expert Opin Investig Drugs. 2012;21:167–180. PMID 22220827
  7. Fassnacht M et al. "European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients with adrenocortical carcinoma." Eur J Endocrinol. 2018;179:G1–G46. PMID 30139921
  8. Baudin E et al. "Pheochromocytoma and functioning paraganglioma in children: a retrospective European Society for Pediatric Endocrinology multicenter study." Eur J Endocrinol. 2013;168:849–58. PMID 23476010
  9. Hescot S et al. "Single-agent molecular targeted therapy for pheochromocytoma." J Clin Endocrinol Metab. 2013;98:2476–84. PMID 23671282
  10. Plouin PF et al. "Pheochromocytoma." Orphanet J Rare Dis. 2012;7:74. PMID 22988945
  11. Thompson LD. "Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to separate benign from malignant neoplasms." Am J Surg Pathol. 2002;26:551–566. PMID 11979086
  12. Niemeijer ND et al. "Succinate dehydrogenase (SDH)-deficient pancreatic cancer." Clin Cancer Res. 2018;24:4137. PMID 29706498

Back to Table of Contents

Back to Table of Contents

Connections

Back to Table of Contents